Several preclinical studies revealed that NEDD4 has cancer chemopreventive and therapeutic capabilities against various malignancies, which include solid tumors such as brain, breast, colon, bladder, liver, pancreas, prostate cancers, etc., and hematological cancers such as lymphoma and leukemia. The gene discussed is NEDD4; the disease is Familial prostate cancer.